Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M3,712Revenue $M0.5Net Margin (%)545Altman Z-Score41.4
Enterprise Value $M3,712EPS $-0.9Operating Margin %550Piotroski F-Score3
P/E(ttm)--Beneish M-Score67.7Pre-tax Margin (%)545Higher ROA y-yN
Price/Book24.310-y EBITDA Growth Rate %-1.1Quick Ratio6.6Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %-8.2Current Ratio6.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-86.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-109.4Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M151ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with IDIX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
IDIXSeth Klarman 2014-09-30 Sold Out -20.7%$23.86 - $24.5
($24.21)
$ 24.501%Sold Out0
IDIXPrem Watsa 2014-09-30 Sold Out -0.08%$23.86 - $24.5
($24.21)
$ 24.501%Sold Out0
IDIXMario Gabelli 2014-09-30 Sold Out -0.02%$23.86 - $24.5
($24.21)
$ 24.501%Sold Out0
IDIXPrem Watsa 2014-06-30 Buy 0.08%$4.94 - $24.12
($10.2)
$ 24.50140%New holding50,400
IDIXMario Gabelli 2014-06-30 Buy 0.02%$4.94 - $24.12
($10.2)
$ 24.50140%New holding142,184
IDIXSeth Klarman 2014-03-31 Add2.25%$5.82 - $8.04
($6.96)
$ 24.50252%Add 44.49%53,331,109
IDIXSeth Klarman 2013-12-31 Add1.24%$3.29 - $6.93
($4.6)
$ 24.50433%Add 24.42%36,910,868
IDIXSeth Klarman 2013-09-30 Add0.43%$3.22 - $5.75
($4.38)
$ 24.50459%Add 10.83%29,665,693
IDIXSeth Klarman 2013-03-31 Add0.61%$3.54 - $5.36
($4.6)
$ 24.50433%Add 25.78%26,042,000
IDIXSeth Klarman 2012-12-31 Add1.35%$3.52 - $5.3
($4.51)
$ 24.50443%Add 72.54%20,704,700
IDIXFirst Eagle Investment 2012-12-31 Sold Out -0.0025%$3.52 - $5.3
($4.51)
$ 24.50443%Sold Out0
IDIXSeth Klarman 2012-09-30 Add0.28%$4.39 - $11.06
($7.89)
$ 24.50211%Add 20.00%12,000,000
IDIXFirst Eagle Investment 2012-09-30 Buy $4.39 - $11.06
($7.89)
$ 24.50211%New holding150,000
IDIXSeth Klarman 2012-06-30 Add0.47%$7.24 - $10.71
($8.92)
$ 24.50175%Add 21.23%10,000,000
IDIXSeth Klarman 2012-03-31 Add0.85%$7.01 - $14.89
($11.02)
$ 24.50122%Add 45.61%8,249,000
IDIXGeorge Soros 2012-03-31 Sold Out -0.08%$7.01 - $14.89
($11.02)
$ 24.50122%Sold Out0
IDIXSeth Klarman 2011-12-31 Add0.73%$4.55 - $8.22
($6.49)
$ 24.50278%Add 126.60%5,665,000
IDIXGeorge Soros 2011-12-31 Add0.08%$4.55 - $8.22
($6.49)
$ 24.50278%Add 1382.72%255,028
IDIXSeth Klarman 2011-09-30 Add0.21%$4.15 - $6.96
($5.68)
$ 24.50331%Add 99.09%2,500,000
IDIXGeorge Soros 2011-09-30 Buy $4.15 - $6.96
($5.68)
$ 24.50331%New holding17,200
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

IDIX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


IDIX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BAUPOST GROUP LLC/MA10% Owner 2014-01-31Buy16,420,241$6.5276.92 view
Fanning PaulSVP, Human Resources 2012-03-16Sell30,000$11.04121.92 view
NOVARTIS AG 2011-02-25Buy3,723$3.71560.38 view
NOVARTIS AG 2010-11-26Buy1,983$5.09381.34 view
NOVARTIS AG 2010-08-13Buy37,214$2.45900 view
HODGSON THOMAS RDirector 2009-12-16Buy25,387$2.141044.86 view
HODGSON THOMAS RDirector 2009-12-14Buy24,613$2.091072.25 view
Weidenbruch JohnEx. VP, Gen. Counsel and Secr. 2009-11-24Buy20,000$1.891196.3 view
NOVARTIS AG10% Owner 2006-06-06Buy365$20.4819.63 view
NOVARTIS AG10% Owner 2006-04-04Buy2,938$16.2350.96 view

Press Releases about IDIX :

    Quarterly/Annual Reports about IDIX:

    News about IDIX:

    Articles On GuruFocus.com
    Prem Watsa Buys 4 New Stocks Aug 13 2014 
    Seth Klarman Tops Guru Scoreboard for First Half 2014 Jul 05 2014 
    The Peril of Being a Copycat Jun 26 2014 
    Seth Klarman Buys Cheniere Energy, Keryx Biopharmaceuticals, Idenix Pharmaceuticals, Sells BP, Fidel May 15 2014 
    Baupost’s Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals May 12 2014 
    2013 - Mistakes of Commission,Omission & Confusion Feb 12 2014 
    Seth Klarman Buys Micron Technology, Theravance, PBF Energy, Sells BP, AIG, Yamana Gold Nov 13 2013 
    Seth Klarman Continues Aggressively Buying Drug Company, Soros Adds Mercury Systems Nov 05 2013 
    The Philosophy and Value of Gurufocus Sep 08 2013 
    Seth Klarman Buys BP, AIG, Elan Corp, Sells News Corp., Oracle May 14 2013 

    More From Other Websites
    Activists want 'imminent retirement' of Ariad CEO Feb 20 2015
    Merck Snags Cubist, Fighter of Superbugs, for $9.5B Dec 08 2014
    Health care M&A leads global deal surge Nov 23 2014
    Biotech targets: Cramer's quality candidates Sep 11 2014
    UPDATE: Deutsche Bank Initiates Coverage On Merck Aug 27 2014
    Achillion Pharmaceuticals Up On Buyout Rumors Aug 18 2014
    Ukraine Tension Prominent As Dow Suffers Triple Digit Loss; S&P 500 & NASDAQ Also Lower Aug 05 2014
    IDENIX PHARMACEUTICALS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Aug 05 2014
    IDENIX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 31 2014
    IDENIX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Jul 31 2014
    Merck, Pfizer Ramping R&D After Q2 Earnings Beat Jul 29 2014
    Merck 2Q profit more than doubles Jul 29 2014
    Every Which Way But Short Jul 24 2014
    [video] Cramer's Stop Trading: Yellen effect Jul 16 2014
    A Pre-Earnings Update On Gilead Jul 10 2014
    Seth Klarman Is Top-Performing Guru for First Half 2014 Jul 05 2014
    A Primer On The Hepatitis C Market Jul 03 2014
    Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline Jul 03 2014
    Idenix (IDIX) is in Overbought Territory: What's Next? Jul 03 2014
    What If Legacy Pharmaceutical And Consumer Business Keeps Falling For Merck? Jun 27 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    Bradlewski
    ReplyBradlewski - 10 months ago
    Merck is buying it for $24.5/share.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK